Language
English
Publication Date
2-24-2025
Journal
Clinical Infectious Diseases
DOI
10.1093/cid/ciae422
PMID
39159048
PMCID
PMC11848279
PubMedCentral® Posted Date
8-19-2024
PubMedCentral® Full Text Version
Post-print
Abstract
Background: Little is known about the potential benefits or harms of statins on physical function among people with human immunodeficiency virus (PWH).
Methods: REPRIEVE was a double-blind randomized controlled trial evaluating pitavastatin for primary prevention of major adverse cardiovascular events in PWH. Time to complete 10 chair rises, 4-m gait speed, grip strength, and a modified short physical performance test were assessed annually for up to 5 years in the ancillary study PREPARE and analyzed using linear mixed models.
Findings: Of 602 PWH, 52% were randomized to pitavastatin and 48% to placebo. Median age was 51 years; 18% were female at birth; 2% transgender; and 40% Black, and 18% Hispanic. Median PREPARE follow-up was 4.7 (4.3-5.0) years. Muscle symptoms (grade ≥3 or treatment-limiting) occurred in 5% of both groups. There was no evidence of decline in chair rise rate in either treatment group and no difference in the pitavastatin group compared to placebo (estimated difference -0.10 [95% confidence interval, -.30 to 0.10] rises/min/year; P = .31). Small declines over time were observed in other physical function tests in both treatment groups, with no apparent differences between groups.
Interpretation: We observed minimal declines in physical function over 5 years of follow-up among middle-aged PWH, with no differences among PWH randomized to pitavastatin compared to placebo. This finding, combined with low prevalence of myalgias, supports the long-term safety of statin therapy on physical function, when used for primary prevention of major adverse cardiovascular events among PWH.
Trial registration: ClinicalTrials.gov NCT02344290 NCT03070223.
Keywords
Humans, Quinolines, Female, Male, Middle Aged, Double-Blind Method, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Adult, HIV Infections, Cardiovascular Diseases, Aged, HIV, physical function, statin, frailty, muscle
Published Open-Access
yes
Recommended Citation
Erlandson, Kristine M; Umbleja, Triin; Ribaudo, Heather J; et al., "Pitavastatin Is Well-Tolerated With no Detrimental Effects on Physical Function" (2025). Faculty and Staff Publications. 4653.
https://digitalcommons.library.tmc.edu/baylor_docs/4653